R A Harrington

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint Overview of clinical trials of glycoprotein IIb-IIIa inhibitors in acute coronary syndromes
    R A Harrington
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 138:276-86. 1999
  2. ncbi request reprint Myocardial ischemia and infarction
    Robert A Harrington
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27705, USA
    J Am Coll Cardiol 44:10A-12A. 2004
  3. ncbi request reprint Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease
    R A Harrington
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Circulation 102:728-35. 2000
  4. ncbi request reprint Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators
    K W Mahaffey
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 99:2371-7. 1999
  5. ncbi request reprint Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy
    J H Alexander
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Am J Cardiol 83:1147-51. 1999
  6. ncbi request reprint First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial
    J H Alexander
    Duke University Center and Duke Clinical Research Institute, Durham, NC 27715, USA
    J Thromb Haemost 3:439-47. 2005
  7. ncbi request reprint Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy
    L K Newby
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 103:2891-6. 2001
  8. ncbi request reprint Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group
    S D Berkowitz
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Am Coll Cardiol 32:311-9. 1998
  9. ncbi request reprint Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II
    B E Tardiff
    Duke Clinical Research Institute, Durham, North Carolina 27710, USA
    J Am Coll Cardiol 33:88-96. 1999
  10. ncbi request reprint Myonecrosis after revascularization procedures
    R M Califf
    Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina, USA
    J Am Coll Cardiol 31:241-51. 1998

Research Grants

  1. Re-Engineering the Clinical Research Enterprise
    Robert Harrington; Fiscal Year: 2004

Collaborators

Detail Information

Publications89

  1. ncbi request reprint Overview of clinical trials of glycoprotein IIb-IIIa inhibitors in acute coronary syndromes
    R A Harrington
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 138:276-86. 1999
    ..Recent approvals of 2 GP IIb-IIIa inhibitors, the peptide eptifibatide and the peptidomimetic tirofiban, mark the beginning of a new era in the management of non-ST-segment elevation ACS...
  2. ncbi request reprint Myocardial ischemia and infarction
    Robert A Harrington
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27705, USA
    J Am Coll Cardiol 44:10A-12A. 2004
  3. ncbi request reprint Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease
    R A Harrington
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Circulation 102:728-35. 2000
    ..We assessed the safety, tolerability, and pharmacodynamics of lotrafiban, an oral platelet glycoprotein IIb/IIIa inhibitor, as a secondary prevention strategy in patients with cerebrovascular or cardiovascular disease...
  4. ncbi request reprint Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators
    K W Mahaffey
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 99:2371-7. 1999
    ..The incidence of stroke in patients with acute coronary syndromes has not been clearly defined because few trials in this patient population have been large enough to provide stable estimates of stroke rates...
  5. ncbi request reprint Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy
    J H Alexander
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Am J Cardiol 83:1147-51. 1999
    ..534). Prior aspirin users had fewer enrollment MIs but worse long-term outcomes than nonusers. We found no evidence for a different treatment effect of eptifibatide in prior aspirin users...
  6. ncbi request reprint First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial
    J H Alexander
    Duke University Center and Duke Clinical Research Institute, Durham, NC 27715, USA
    J Thromb Haemost 3:439-47. 2005
    ..Anticoagulants with predictable kinetics and anticoagulant effects, better efficacy, and greater safety are needed...
  7. ncbi request reprint Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy
    L K Newby
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 103:2891-6. 2001
    ..Troponin T (TnT) is valuable for short- and long-term risk stratification of patients with acute coronary syndromes (ACS). It also may predict which ACS patients will benefit from glycoprotein (GP) IIb/IIIa blockade...
  8. ncbi request reprint Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group
    S D Berkowitz
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Am Coll Cardiol 32:311-9. 1998
    ....
  9. ncbi request reprint Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II
    B E Tardiff
    Duke Clinical Research Institute, Durham, North Carolina 27710, USA
    J Am Coll Cardiol 33:88-96. 1999
    ....
  10. ncbi request reprint Myonecrosis after revascularization procedures
    R M Califf
    Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina, USA
    J Am Coll Cardiol 31:241-51. 1998
    ..In addition, tracking of enzyme levels in clinical trials is needed to determine whether interventions that reduce periprocedural enzyme elevation also improve mortality...
  11. ncbi request reprint Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial
    M T Roe
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 102:1101-6. 2000
    ..A proportion of patients who present with suspected acute coronary syndrome (ACS) are found to have insignificant coronary artery disease (CAD) during coronary angiography, but these patients have not been well characterized...
  12. ncbi request reprint Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Usin
    J H Alexander
    Duke Clinical Research Institute, Durham, NC 27715, USA
    JAMA 283:347-53. 2000
    ..Controversy surrounds the diagnostic and prognostic importance of slightly elevated cardiac markers in patients with acute coronary syndromes without ST-segment elevation...
  13. ncbi request reprint Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes
    D B Mark
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
    Circulation 101:366-71. 2000
    ..In the PURSUIT trial, eptifibatide significantly reduced the 30-day incidence of death and myocardial infarction relative to placebo in 9461 patients with an acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction)...
  14. doi request reprint Dose selection for a direct and selective factor IXa inhibitor and its complementary reversal agent: translating pharmacokinetic and pharmacodynamic properties of the REG1 system to clinical trial design
    T J Povsic
    Division of Cardiology, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
    J Thromb Thrombolysis 32:21-31. 2011
    ..The 1 mg/kg pegnivacogin dose and a range of anivamersen dose ratios are being tested in the phase 2b RADAR study (NCT00932100)...
  15. ncbi request reprint Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up
    K P Alexander
    Outcomes Research and Assessment Group, The Duke Clinical Research Institute, Durham, North Carolina 27710, USA
    J Am Coll Cardiol 38:1-7. 2001
    ..This study explored the association between the initiation of hormone replacement therapy (HRT) and early cardiac events (<1 year) in women with a recent myocardial infarction (MI)...
  16. ncbi request reprint Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators
    A B Greenbaum
    Division of Cardiology, Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina, USA
    J Am Coll Cardiol 37:492-8. 2001
    ....
  17. ncbi request reprint Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion
    M T Roe
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    J Am Coll Cardiol 37:9-18. 2001
    ..Thus, as the reperfusion era moves into the next millennium, the open-artery hypothesis is expected to shift downstream and guide efforts to further improve myocardial salvage and clinical outcomes after acute MI...
  18. ncbi request reprint Prognostic value of congestive heart failure history in patients undergoing percutaneous coronary interventions
    R D Anderson
    Duke Clinical Research Institute, Durham, North Carolina, USA
    J Am Coll Cardiol 32:936-41. 1998
    ..We sought to determine the prognostic significance of a history of congestive heart failure above that provided by baseline ejection fraction in patients undergoing percutaneous coronary interventions...
  19. doi request reprint Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation
    R D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt Street, Room 0311 Terrace Level, Durham, NC 27707, USA
    Heart 94:867-73. 2008
    ....
  20. ncbi request reprint Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS)
    C M O'Connor
    Department of Medicine, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27710, USA
    Am J Cardiol 88:541-6. 2001
    ..The results of this secondary analysis suggest that aspirin 160 mg is more effective than aspirin 80 mg + warfarin 1 mg in preventing ischemic stroke in post-myocardial infarction patients...
  21. ncbi request reprint Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT
    B E Tardiff
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 104:399-405. 2001
    ..These results enhance our understanding of the relation between pharmacodynamic and clinical effects of eptifibatide in such patients and may have important implications for its use in percutaneous interventions...
  22. ncbi request reprint Recent clinical trials in acute coronary syndromes without persistent ST elevation
    T R Tolleson
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Curr Opin Cardiol 14:403-11. 1999
    ..Debate continues as to whether a strategy of early intervention or initial conservative management is most appropriate. Continued clinical trials will help define optimal treatment strategies in this high-risk group of patients...
  23. doi request reprint A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor
    M Y Chan
    Duke Clinical Research Institute, Durham, NC 27705, USA
    J Thromb Haemost 6:789-96. 2008
    ..RB006, a ribonucleic acid aptamer, exerts its anticoagulant effect by selectively binding FIXa. RB007, the complementary oligonucleotide antidote, binds to RB006 by Watson-Crick base pairing, neutralizing its anti-FIXa activity...
  24. ncbi request reprint GP IIb/IIIa blockade in elective percutaneous coronary intervention
    J P Dery
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
    Curr Pharm Des 10:387-98. 2004
    ..The following review will discuss the scientific grounds and the principal controversies surrounding the use of these compounds in patients undergoing elective percutaneous coronary intervention...
  25. ncbi request reprint Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot
    J H Alexander
    Duke University Medical Center and Duke Clinical Research Institute, Durham, NC 27715, USA
    J Thromb Haemost 2:234-41. 2004
    ..Direct factor (F)Xa inhibition is an attractive method to limit thrombotic complications during percutaneous coronary intervention (PCI)...
  26. ncbi request reprint Variation in patient management and outcomes for acute coronary syndromes in Latin America and North America: results from the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial
    M G Cohen
    Duke Clinical Research Institute, Durham, NC, USA
    Am Heart J 141:391-401. 2001
    ..We sought to compare characteristics, resource utilization, and outcomes of patients treated for acute coronary syndromes in Latin America with those in North America...
  27. ncbi request reprint Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes
    M T Roe
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Eur Heart J 25:313-21. 2004
    ..To study the relationship between outcomes and peak creatine kinase (CK)-MB levels after percutaneous coronary intervention (PCI) in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS)...
  28. ncbi request reprint Predictors of 90-day outcome in patients stabilized after acute coronary syndromes
    L K Newby
    Duke Clinical Research Institute, Durham, NC 27715 7969, USA
    Eur Heart J 24:172-81. 2003
    ..We investigated predictors of 90-day risk among patients surviving the early period after an acute coronary syndrome (ACS)...
  29. ncbi request reprint Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative
    Kanwar P Singh
    Division of Cardiology and Duke Clinical Research Institute, Durham, NC 27705, USA
    J Thromb Thrombolysis 21:211-20. 2006
    ..We sought to compare the efficacy and safety of these treatment strategies in a large contemporary population of patients with NSTE ACS...
  30. ncbi request reprint Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutan
    J Emilio Exaire
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 152:157-63. 2006
    ..Provisional drug was used in 374 (6%) of the 6010 patients. We sought to analyze the predictors for provisional drug use and to assess the outcomes in this cohort...
  31. ncbi request reprint Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials
    John M Galla
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 151:16-24. 2006
    ..A concomitant goal was to contribute insight to the debate over how patients with NSTE ACS should be managed...
  32. ncbi request reprint Relation of early saphenous vein graft failure to outcomes following coronary artery bypass surgery
    Abdul R Halabi
    Division of Cardiology, Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 96:1254-9. 2005
    ..36, 95% confidence interval 2.00 to 2.79, p <0.0001). In conclusion, in contemporary clinical practice, early SVG failure is associated with worse long-term outcomes after CABG...
  33. ncbi request reprint The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with n
    Robert P Giugliano
    TIMI Study Group, Boston, MA 02115, USA
    Am Heart J 149:994-1002. 2005
    ..However, the guidelines are not explicit regarding the timing of initiation of GpIIb-IIIa antagonists, and there is marked variation in clinical practice regarding their use...
  34. ncbi request reprint Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial
    Hitinder S Gurm
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Am Coll Cardiol 45:1932-8. 2005
    ..The objective of this study was to confirm that the efficacy and safety of percutaneous coronary intervention (PCI) in diabetic patients are not compromised by a bivalirudin-based antithrombotic strategy...
  35. ncbi request reprint Early glycoprotein IIb/IIIa inhibitor use for non-ST-segment elevation acute coronary syndrome: patient selection and associated treatment patterns
    James W Hoekstra
    Department of Emergency Medicine, Wake Forest University Health Sciences, Medical Center Boulevard, Winston Salem, NC 27157, USA
    Acad Emerg Med 12:431-8. 2005
    ....
  36. ncbi request reprint Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials)
    Abdallah G Rebeiz
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 95:611-4. 2005
    ..7% vs 48.0% with >/=50% ST-segment resolution, p = 0.03) and sustained over 180 minutes after drug administration; this transient benefit may suggest a time frame when more optimal percutaneous coronary intervention can be performed...
  37. ncbi request reprint Angiographic and clinical outcomes associated with direct versus conventional stenting among patients treated with fibrinolytic therapy for ST-elevation acute myocardial infarction
    Hung Q Ly
    Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 95:383-6. 2005
    ..44, 95% confidence interval 0.23 to 0.85, p = 0.014)...
  38. ncbi request reprint Care of non-ST-segment elevation patients: insights from the CRUSADE national quality improvement initiative
    E Magnus Ohman
    Division of Cardiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Am Heart J 148:S34-9. 2004
    ..These ACC/AHA guidelines are intended to help physicians make appropriate decisions when diagnosing and treating patients with NSTE ACS...
  39. ncbi request reprint Advances in antithrombotic therapy in acute myocardial infarction: the ExTRACT-TIMI 25 and OASIS-6 Trials
    John H Alexander
    Curr Cardiol Rep 8:279-81. 2006
  40. ncbi request reprint Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention
    Gilles Montalescot
    Institut de Cardiologie, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    N Engl J Med 355:1006-17. 2006
    ..Several small studies have suggested that intravenous enoxaparin may be a safe and effective alternative. Our primary aim was to assess the safety of enoxaparin as compared with that of unfractionated heparin in elective PCI...
  41. ncbi request reprint Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal
    Warren J Cantor
    Division of Cardiology, St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
    Catheter Cardiovasc Interv 69:73-83. 2007
    ..Our objective was to analyze the impact of arterial access site, sheath size, timing of sheath removal, and use of access site closure devices on high-risk patients with acute coronary syndromes (ACS)...
  42. doi request reprint Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PRoject of Ex-vivo Vein graft ENgineering via Transfection [PREVENT] IV)
    James M Yau
    Duke University Medical Center, Durham, North Carolina, USA
    Am J Cardiol 102:546-51. 2008
    ..Further research is needed into the prevention and treatment of perioperative MI in patients undergoing CABG...
  43. doi request reprint Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndrome
    Steve Leung
    University of Kentucky, Lexington, KY, USA
    Am Heart J 156:177-84. 2008
    ..Smoking remains a major public health issue. We investigated the incidence of smoking and outcomes in high-risk patients with acute coronary syndromes. Differences in treatment effect of antithrombin therapies were also investigated...
  44. doi request reprint Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    Shaun G Goodman
    St Michael s Hospital, Division of Cardiology, 30 Bond Street, Queen, Toronto, Ontario, Canada
    Chest 133:708S-775S. 2008
    ....
  45. doi request reprint A randomized, double-blind, placebo-controlled, multicenter study to evaluate the cardioprotective effects of MC-1 in patients undergoing high-risk coronary artery bypass graft surgery: MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft
    Rajendra H Mehta
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 155:600-8. 2008
    ....
  46. doi request reprint Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes
    Chiara Melloni
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27705, USA
    J Am Coll Cardiol 51:991-6. 2008
    ..Our purpose was to compare formulae for estimating glomerular filtration rate (GFR) in non-ST-segment elevation acute coronary syndromes (NSTE ACS) patients...
  47. doi request reprint Impact of saphenous vein graft radiographic markers on clinical events and angiographic parameters
    Stephen A Olenchock
    Cardiothoracic Surgery Department, Tufts University School of Medicine and Caritas St Elizabeth s Medical Center, Boston, Massachusetts, USA
    Ann Thorac Surg 85:520-4. 2008
    ..The goal of the present analysis was to evaluate the association of SVG markers with clinical outcomes and graft patency...
  48. doi request reprint Coronary artery bypass graft failure after on-pump and off-pump coronary artery bypass: findings from PREVENT IV
    Mitchell J Magee
    Cardiopulmonary Research Science and Technology Institute, Dallas, Texas, USA
    Ann Thorac Surg 85:494-9; discussion 499-500. 2008
    ....
  49. ncbi request reprint Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
    Christopher P Cannon
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 50:1844-51. 2007
    ..Our goal was to compare the safety and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, with clopidogrel in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS)...
  50. ncbi request reprint Clinical decisions. Management of stable coronary disease
    Salim Yusuf
    McMaster University, Hamilton, ON, Canada
    N Engl J Med 357:1762-6. 2007
  51. ncbi request reprint Effects of pyridoxal-5'-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery: results of the MEND-CABG randomized study
    Jean Claude Tardif
    Montreal Heart Institute, Montreal, Canada
    J Thorac Cardiovasc Surg 133:1604-11. 2007
    ..The MEND-CABG trial tested the hypothesis that MC-1 reduces cardiovascular morbidity and mortality after coronary artery bypass graft...
  52. ncbi request reprint Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery
    Abhinav Goyal
    Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Ann Thorac Surg 83:993-1001. 2007
    ..We investigated whether greater use of secondary prevention medications after coronary artery bypass graft surgery is associated with improved clinical outcomes...
  53. ncbi request reprint Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial
    Jean Pierre Dery
    Department of Cardiology, The Quebec Heart and Lung Institute, Quebec, Canada
    Catheter Cardiovasc Interv 70:43-50. 2007
    ..This analysis sought to investigate the complementary effect of thienopyridine pretreatment and platelet glycoprotein (GP) IIb/IIIa integrin blockade in coronary stent intervention...
  54. ncbi request reprint Late ischemic events after clopidogrel cessation following drug-eluting stenting: should we be worried?
    Robert A Harrington
    J Am Coll Cardiol 48:2592-5. 2006
  55. ncbi request reprint Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revas
    Harvey D White
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    Am Heart J 152:1042-50. 2006
    ..The SYNERGY trial compared these agents in high-risk patients undergoing early invasive treatment. Enoxaparin was noninferior to UFH for the 30-day primary end point of death/myocardial infarction (MI), but modestly increased bleeding...
  56. ncbi request reprint Cardiac tamponade in the fibrinolytic era: analysis of >100,000 patients with ST-segment elevation myocardial infarction
    Manesh R Patel
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 151:316-22. 2006
    ..Cardiac tamponade is a life-threatening complication of acute myocardial infarction (MI). Data on the incidence, risk factors, and outcome of tamponade in patients with acute MI in the fibrinolytic era are limited...
  57. ncbi request reprint Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
    Jeffrey J Popma
    Interventional Cardiology, Brigham and Women s Hospital, 75 Francis St, Tower 2 3A Room 311, Boston, MA 02115, USA
    Chest 126:576S-599S. 2004
    ..In patients who undergo PCI with no other indication for systemic anticoagulation therapy, we recommend against routine use of vitamin K antagonists after PCI (Grade 1A)...
  58. ncbi request reprint Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
    Venu Menon
    Division of Cardiology, University of North Carolina at Chapel Hill, 27599, USA
    Chest 126:549S-575S. 2004
    ....
  59. ncbi request reprint Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease
    Eric J Topol
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Circulation 108:399-406. 2003
    ....
  60. ncbi request reprint Effect of revascularization on mortality associated with an elevated white blood cell count in acute coronary syndromes
    Deepak L Bhatt
    Department of Cardiovascular Medicine Desk F25, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Am J Cardiol 92:136-40. 2003
    ..This finding supports a pivotal role for inflammation in acute coronary syndromes. Importantly, this study suggests that in-hospital revascularization may mitigate some of the excess risk due to inflammation...
  61. ncbi request reprint Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial
    A Michael Lincoff
    Department of Cardiovascular Medicine, Desk F25, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
    JAMA 289:853-63. 2003
    ....
  62. ncbi request reprint Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial
    Thaddeus R Tolleson
    Duke University Medical Center and Clinical Research Institute, Durham, NC 27705, USA
    J Am Coll Cardiol 41:386-93. 2003
    ..We evaluated the relationship between the degree of heparin anticoagulation and clinical efficacy and bleeding in patients undergoing contemporary percutaneous coronary intervention (PCI) with stent implantation...
  63. ncbi request reprint Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients
    Padma Kaul
    Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA
    J Am Coll Cardiol 41:371-80. 2003
    ....
  64. ncbi request reprint Characteristics, treatment and outcome of patients with non-ST-elevation acute coronary syndromes and multivessel coronary artery disease: observations from PURSUIT (platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrelin
    Arno Breeman
    Thorax Center, Erasmus University Medical Center, Rotterdam, The Netherlands
    Cardiology 98:195-201. 2002
    ..e. medical treatment, percutaneous coronary intervention (PCI) (balloon), PCI (stent), or coronary artery bypass grafting (CABG)...
  65. ncbi request reprint Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials
    David Hasdai
    Rabin Medical Center, Petah Tikva, Israel
    Am Heart J 145:73-9. 2003
    ..Our objective was to determine the incidence, timing, and consequences of mild-to-moderate HF complicating acute MI...
  66. ncbi request reprint Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B)
    Debabrata Mukherjee
    University of Michigan Health System, Ann Arbor, Mich, USA
    Am Heart J 144:995-1002. 2002
    ..Minimal data are available on LMWH combined with platelet glycoprotein (GP) IIb/IIIa inhibitors...
  67. ncbi request reprint Improving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department: the CRUSADE initiative
    James W Hoekstra
    Ohio State University, Columbus, OH 43210, USA
    Acad Emerg Med 9:1146-55. 2002
    ..It is the intent of CRUSADE to improve patient care in the ED by tracking and encouraging compliance with evidence-based guidelines for the evaluation and management of NSTE ACS...
  68. ncbi request reprint Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, an
    Wayne B Batchelor
    Tallahassee Heart and Vascular Institute, Tallahassee Memorial Healthcare, Tallahassee, Fla 32308, USA
    Circulation 106:1470-6. 2002
    ..The relative anti-aggregatory effects of currently prescribed platelet glycoprotein IIb/IIIa receptor antagonists during and after percutaneous coronary intervention for acute coronary syndromes have not been established...
  69. ncbi request reprint Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes
    Jassim Al Suwaidi
    Mayo Clinic and Foundation, Rochester, Minn 55905, USA
    Circulation 106:974-80. 2002
    ..Outcomes in patients with mild to moderate renal function (RF) abnormalities presenting with acute coronary syndromes (ACS) are not well defined...
  70. ncbi request reprint First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation
    Christopher K Dyke
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Circulation 105:2385-91. 2002
    ....
  71. ncbi request reprint Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different?
    K Martijn Akkerhuis
    Thoraxcenter, University Hospital Rotterdam, The Netherlands
    Circulation 105:554-6. 2002
    ....
  72. ncbi request reprint Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials
    Eric Boersma
    University Hospital Rotterdam, Rotterdam, The Netherlands
    Lancet 359:189-98. 2002
    ....
  73. ncbi request reprint Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials)
    Thaddeus R Tolleson
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 92:330-3. 2003
    ..These patients and their outcomes may be more representative of patients with typical acute coronary syndromes undergoing stenting in clinical practice...
  74. ncbi request reprint Cardiology patient page. Antiplatelet therapy
    Robert A Harrington
    Duke Clinical Research Institute, 2400 Pratt St, Durham, NC 27705, USA
    Circulation 108:e45-7. 2003
  75. ncbi request reprint Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase
    C Michael Gibson
    TIMI Study Group and the Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass, USA
    Circulation 110:679-84. 2004
    ....
  76. ncbi request reprint Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview
    John L Petersen
    Duke Clinical Research Institute, Durham, NC 27715, USA
    JAMA 292:89-96. 2004
    ....
  77. ncbi request reprint Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial
    Marino Labinaz
    University of Ottawa Heart Institute, Ottawa, Ontario
    Can J Cardiol 20:773-8. 2004
    ..For patients with ACS undergoing percutaneous balloon angioplasty without coronary stenting in the era of platelet glycoprotein IIb/IIIa blockade, the long-term prognosis is less clear...
  78. ncbi request reprint Dynamic prognostication in non-ST-elevation acute coronary syndromes: insights from GUSTO-IIb and PURSUIT
    Wei Ching Chang
    University of Alberta, Edmonton, Alberta, Canada
    Am Heart J 148:62-71. 2004
    ..The objective of the current study was to develop an approach to predicting outcome in NSTE-ACS that could account for the changing nature of risk...
  79. ncbi request reprint Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion
    Robert P Giugliano
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 350 Longwood Avenue, 1st Floor Offices, Boston, MA 02115, USA
    Am J Cardiol 93:1362-7, A5-6. 2004
    ..This new end point is proposed to evaluate the success of reperfusion therapy in patients who undergo early angiography...
  80. ncbi request reprint Association of the timing of ST-segment resolution with TIMI myocardial perfusion grade in acute myocardial infarction
    C Michael Gibson
    TIMI Study Group, The Department of Medicine, Brigham and Women s Hospital, Boston, Mass, USA
    Am Heart J 147:847-52. 2004
    ..However, no data exist comparing the speed of ST resolution on continuous electrocardiogram (ECG) monitoring with the TMPG on coronary angiography. We hypothesized that delayed ST res is associated with impaired TMPGs...
  81. ncbi request reprint Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial)
    A Michael Lincoff
    Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Cardiol 93:1092-6. 2004
    ..52). This trial represents the largest prospective dataset of bivalirudin administered concomitantly with planned GP IIb/IIIa blockade and provides evidence of the safety and efficacy of this combined antithrombotic approach...
  82. ncbi request reprint Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction
    C Michael Gibson
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 43:1170-6. 2004
    ....
  83. ncbi request reprint Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial
    Robert P Giugliano
    TIMI Study Group, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 41:1251-60. 2003
    ..The goal of this study was to evaluate combinations of eptifibatide with reduced-dose tenecteplase (TNK) in ST-elevation myocardial infarction (STEMI)...
  84. ncbi request reprint Glycoprotein IIb/IIIa receptor antagonists: a comparative review of their use in percutaneous coronary intervention
    Can M Nguyen
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    Am J Cardiovasc Drugs 3:423-36. 2003
    ....
  85. ncbi request reprint Evaluating the benefits of glycoprotein IIb/IIIa inhibitors in heart failure at baseline in acute coronary syndromes
    Monvadi B Srichai
    Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am Heart J 147:84-90. 2004
    ....
  86. ncbi request reprint Prognostic importance of physical examination for heart failure in non-ST-elevation acute coronary syndromes: the enduring value of Killip classification
    Umesh N Khot
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    JAMA 290:2174-81. 2003
    ..Although well studied in ST-elevation myocardial infarction, the prognostic importance of Killip classification in non-ST-elevation acute coronary syndromes is not well established...
  87. ncbi request reprint Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study
    James J Ferguson
    Cardiology Research 1 191, St Luke s Episcopal Hospital, Houston, Tex 77225, USA
    Am Heart J 146:628-34. 2003
    ....
  88. ncbi request reprint Association between admission white blood cell count and one-year mortality in patients with acute coronary syndromes
    Michael H Yen
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Med 115:318-21. 2003
  89. ncbi request reprint Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial
    Marino Labinaz
    University of Ottawa Heart Institute, Ottawa, Ontario, Canada
    Circulation 105:322-7. 2002
    ..90 [95% CI, 0.67 to 1.20]) and in patients without a history of CABG (unadjusted HR, 0.89 [95% CI, 0.80 to 0.99])...

Research Grants1

  1. Re-Engineering the Clinical Research Enterprise
    Robert Harrington; Fiscal Year: 2004
    ....